Palliation of bone pain in prostate cancer using chemotherapy and strontium-89. A randomized phase II study

Journal of Pain and Symptom Management

Volumn 29, Issue 4, 2005, Pages 352-357

  Nilsson, Sten ^a   Strang, Peter ^b   Ginman, Claes ^c   Zimmermann, Rolf ^d   Edgren, Maliha ^e   Nordström, Britta ^a   Ryberg, Marianne ^a   Kälkner, Karl Mikael ^a   Westlin, Jan Erik ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c CENTRAL HOSPITAL   (Sweden)

^d Univ Hospital South Hospital   (Sweden)

^e Central Hospital   (Sweden)

Author keywords

Chemotherapy; Inflammation; Neoplasms; Pain; Prostate; Strontium

Indexed keywords

EPIRUBICIN; FLUOROURACIL; MITOMYCIN C; STRONTIUM 89;

ADULT; AGED; ARTICLE; BONE PAIN; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HUMAN; MALE; PAIN ASSESSMENT; PALLIATIVE THERAPY; PHASE 2 CLINICAL TRIAL; PROSTATE CARCINOMA; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SIDE EFFECT;

EID: 18044378963     PISSN: 08853924     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpainsymman.2004.07.008     Document Type: Article

References (37)

1. World Health Organization Cancer pain relief and palliative care 2nd ed. 1996 World Health Organization Geneva
2. R.K. Portenoy, and P. Lesage Management of cancer pain Lancet 353 9165 1999 1695 1700
3. H.J. McQuay, S.L. Collins, D. Carroll, and R.A. Moore Radiotherapy for the palliation of painful bone metastases Cochrane Database Syst Rev 2 2000 CD001793
4. P.J. Hoskin, J.R. Yarnold, D.R. Roos, and S. Bentzen Radiotherapy for bone metastases Clin Oncol (R Coll Radiol) 13 2 2001 88 90
5. G. Arcangeli, A. Micheli, and D. Giannarelli The responsiveness of bone metastases to radiotherapy: The effect of site, histology and radiation dose on pain relief Radiother Oncol 14 2 1989 95 101
6. P.H. Blitzer Reanalysis of the RTOG study of the palliation of symptomatic osseous metastasis Cancer 55 7 1985 1468 1472
7. A. Ambrad Single dose and short, high dose fractionation radiation therapy for osseous metastases Int J Radiat Oncol Biol Phys 4 1978 207 208
8. F.R. Hendrickson, W.M. Shehata, and A.B. Kirchner Radiation therapy for osseous metastasis Int J Radiat Oncol Biol Phys 1 3-4 1976 275 278
9. L. Trodella, G. Ausili-Cefaro, and A. Turriziani Pain in osseous metastases: Results of radiotherapy Pain 18 4 1984 387 396
10. O.M. Salazar, P. Rubin, and F.R. Hendrickson Single-dose half-body irradiation for palliation of multiple bone metastases from solid tumors. Final Radiation Therapy Oncology Group report Cancer 58 1 1986 29 36
11. D.A. Kuban, T. Delbridge, A.M. el-Mahdi, and P.F. Schellhammer Half-body irradiation for treatment of widely metastatic adenocarcinoma of the prostate J Urol 141 3 1989 572 574
12. M.J. Zelefsky, H.I. Scher, and J.D. Forman Palliative hemiskeletal irradiation for widespread metastatic prostate cancer: A comparison of single dose and fractionated regimens Int J Radiat Oncol Biol Phys 17 6 1989 1281 1285
13. C. Pecher Biological investigations with radioactive calcium and strontium: Preliminary report on the use of radioactive strontium in treatment of metastatic bone cancer UC Publ Pharmacol 11 1942 117 149
14. R.G. Robinson, G.M. Blake, and D.F. Preston Strontium-89: Treatment results and kinetics in patients with painful metastatic prostate and breast cancer in bone Radiographics 9 2 1989 271 281
15. Laing Hea Strontium-89 chloride for pain palliation in prostatic skeletal malignancy Br J Radiol 64 1991 816 822
16. V.J. Lewington, A.J. McEwan, and D.M. Ackery A prospective, randomized double-blind crossover study to examine the efficacy of strontium-89 in pain palliation in patients with advanced prostate cancer metastatic to bone Eur J Cancer 27 8 1991 954 958
17. P.M. Quilty, D. Kirk, and J.J. Bolger A comparison of the palliative effects of strontium-89 and external beam radiotherapy in metastatic prostate cancer Radiother Oncol 31 1 1994 33 40
18. R.G. Robinson, D.F. Preston, M. Schiefelbein, and K.G. Baxter Strontium-89 therapy for the palliation of pain due to osseous metastases JAMA 274 5 1995 420 424
19. S.L. Turner, S. Gruenewald, and N. Spry Less pain does equal better quality of life following strontium-89 therapy for metastatic prostate cancer Brit J Cancer 84 3 2001 297 302
20. K.M. Kalkner, J.E. Westlin, and P. Strang 89Strontium in the management of painful skeletal metastases [review] Anticancer Research 20 2B 2000 1109 1114
21. F. Kraeber-Bodere, L. Campion, and C. Rousseau Treatment of bone metastases of prostate cancer with strontium-89 chloride: Efficacy in relation to the degree of bone involvement Eur J Nucl Med 27 10 2000 1487 1493
22. P.W. Kantoff, S. Halabi, and M. Conaway Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: Results of the cancer and leukemia group B 9182 study [comment] J Clin Oncol 17 8 1999 2506 2513
23. S.D. Huan, R.B. Natale, and D.J. Stewart A multicenter phase II trial of losoxantrone (DuP-941) in hormone-refractory metastatic prostate cancer Clin Cancer Res 6 4 2000 1333 1336
24. R. Petrioli, A.I. Fiaschi, and D. Pozzessere Weekly epirubicin in patients with hormone-resistant prostate cancer Brit J Cancer 87 7 2002 720 725
25. S. Urakami, M. Igawa, and N. Kikuno Combination chemotherapy with paclitaxel, estramustine and carboplatin for hormone refractory prostate cancer [comment] J Urol 168 6 2002 2444 2450
26. M. Sitka Copur, P. Ledakis, and J. Lynch Weekly docetaxel and estramustine in patients with hormone-refractory prostate cancer Semin Oncol 28 4 Suppl 15 2001 16 21
27. A.B. Kornblith, J.E. Herndon 2nd, and E. Zuckerman The impact of docetaxel, estramustine, and low dose hydrocortisone on the quality of life of men with hormone refractory prostate cancer and their partners: A feasibility study Ann Oncol 12 5 2001 633 641
28. I.F. Tannock, D. Osoba, and M.R. Stockler Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: A Canadian randomized trial with palliative end points J Clin Oncol 14 6 1996 1756 1764
29. A. Di Leo, E. Bajetta, and R. Buzzoni Epirubicin plus medroxyprogesterone as second-line treatment of advanced prostatic cancer. A study by the Italian Trials in Medical Oncology Group Am J Clin Oncol 18 3 1995 239 244
30. N. MacDonald Principles governing the use of cancer chemotherapy in palliative medicine H. Doyle N. MacDonald Oxford textbook of palliative medicine 1993 Oxford University Press Oxford 105 117
31. R. Sciuto, A. Festa, and S. Rea Effects of low-dose cisplatin on 89Sr therapy for painful bone metastases from prostate cancer: A randomized clinical trial [comment] J Nucl Med 43 1 2002 79 86
32. S.M. Tu, R.E. Millikan, and B. Mengistu Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: A randomized phase II trial [comment] [erratum appears in Lancet 2001 Apr 14;357(9263):1210] Lancet 357 9253 2001 336 341
33. W. McBride Phenotype and functions of intratumoral macrophages Biochem Biophys Acta 865 1986 27 41
34. W. Johnson, M. DiMartino, and P.C. Meunier Methotrexate inhibits macrophage activation as well as vascular and cellular inflammatory events in rat adjuvant induced arthritis J Rheumatol 15 1988 745 749
35. L. Watkins, S. Maier, and L. Goehler Immune activation: The role of pro-inflammatory cytokines in inflammation, illness responses and pathological pain states Pain 63 1995 289 302
36. M. Abu-Shakra, D. Buskila, and M. Ehrenfeld Cancer and autoimmunity: Autoimmune and rheumatic features in patients with malignancies Ann Rheum Dis 60 2001 433 440
37. E. Bruera, E. Roca, and L. Cedaro Action of oral methylprednisolone in terminal cancer patients: A prospective randomized double-blind study Cancer Treat Rep 69 7-8 1985 751 754